Cargando…

DPP-4 inhibitors and severe course of illness in patients with COVID-19

Detalles Bibliográficos
Autores principales:	Bouhanick, Béatrice, Cracowski, Jean-Luc, Faillie, Jean-Luc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816885/ https://www.ncbi.nlm.nih.gov/pubmed/33518293 http://dx.doi.org/10.1016/j.therap.2021.01.051

Ejemplares similares

Diabetes and COVID-19
por: Bouhanick, Béatrice, et al.
Publicado: (2020)

Diabète et COVID-19
por: Bouhanick, Béatrice, et al.
Publicado: (2020)

Drugs acting on renin angiotensin system and use in ill patients with COVID-19
por: Alexandre, Joachim, et al.
Publicado: (2020)

Renin-angiotensin-aldosterone system and COVID-19 infection
por: Alexandre, Joachim, et al.
Publicado: (2020)

Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic
por: Cracowski, Jean-Luc, et al.
Publicado: (2020)

COVID-19: Pharmacology has kept the science ship running during the storm
por: Molimard, Mathieu, et al.
Publicado: (2021)

A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Benefit-risk balance of COVID drugs. New prospects
por: Cracowski, Jean-Luc, et al.
Publicado: (2022)

Adverse drug reactions associated with ivermectin use for COVID-19 reported in the World Health Organization's pharmacovigilance database
por: Campillo, Jeremy T., et al.
Publicado: (2022)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Adverse event reporting and Bell's palsy risk after COVID-19 vaccination
por: Khouri, Charles, et al.
Publicado: (2021)

DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
por: Nag, Snehasish, et al.
Publicado: (2023)

DPP4 inhibition prevents AKI
por: Reichetzeder, Christoph, et al.
Publicado: (2017)

Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma
por: Horie, Kuniko, et al.
Publicado: (2023)

The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients
por: Du, Hengzhi, et al.
Publicado: (2020)

Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review
por: Grange, Lucile, et al.
Publicado: (2020)

Understanding the variability of pharmaco‐epidemiological studies assessing the risk of appendicitis with mRNA COVID‐19 vaccines
por: Jambon‐Barbara, Clement, et al.
Publicado: (2022)

Reply to letter to the editor regarding “Use of DPP-4 inhibitors in patients with COVID-19”
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

DPP4 Inhibitors and COVID-19–Holy Grail or Another Dead End?
por: Krejner-Bienias, Alicja, et al.
Publicado: (2021)

Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity
por: Posadas-Sánchez, Rosalinda, et al.
Publicado: (2021)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
por: Bae, Ji Cheol
Publicado: (2022)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

Impact of global warming on Raynaud’s phenomenon: a modelling study
por: Khouri, Charles, et al.
Publicado: (2020)

Laser speckle contrast imaging to assess microcirculation
por: Hellmann, Marcin, et al.
Publicado: (2022)

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
por: Rhee, Sang Youl, et al.
Publicado: (2021)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020)

Impact of Vaccine Hesitancy on Onset, Severity and Type of Self-reported Adverse Events: A French Cross-Sectional Survey
por: Khouri, Charles, et al.
Publicado: (2022)

Acute myocardial infarction associated to DPP-4 inhibitors
por: Nunes, J P L, et al.
Publicado: (2014)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo, Eleonora, et al.
Publicado: (2013)

COVID-19, severe mental illness, and family violence
por: Wildman, Emilie K., et al.
Publicado: (2021)

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
por: Wang, Aiying, et al.
Publicado: (2012)

DPP-4 Inhibitor-associated Bullous Pemphigoid in a Hemodialysis Patient
por: Usami, Jun, et al.
Publicado: (2019)

Aerial view of the Echevenex's gold course. In the background, Point 4.
por: Jean-Luc Caron
Publicado: (1996)

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
por: Sebastián-Martín, Alba, et al.
Publicado: (2022)

Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: a nationwide repeated cohort study
por: Mathieu, Clément, et al.
Publicado: (2022)

Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study
por: Faillie, Jean-Luc, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_31hj1bcnuha13t7bop57v1m64u